Our team is composed of highly experienced professionals with deep expertise in health economics, health technology assessment (HTA), market access strategies, and patient preferences studies. Together, we bring decades of combined experience in research, consultancy, and academic leadership, offering a comprehensive approach to healthcare evaluation and decision-making.
With a strong foundation in health economic evaluation, decision-analytic modeling, and patient preferences our team members have contributed extensively to advancing HTA methodologies and processes. Their expertise spans a wide range of clinical areas, including oncology, cardiology, respiratory and rheumatic disorders, and mental health, as well as innovative approaches for evaluating emerging medical technologies such as cell and gene therapies.
Our team’s background also includes significant advisory roles with regulatory and reimbursement bodies, such as the National Institute for Health and Care Excellence (NICE), as well as collaborations with pharmaceutical companies and global consultancy firms. This blend of academic and industry experience ensures that our insights are grounded in both cutting-edge research and practical applications.
We specialize in market access strategies and patient-centered outcomes research, with a deep understanding of diverse healthcare environments, including the Greek market. Our expertise in economic evaluations, evidence synthesis, and patient preference studies equips us to deliver robust and tailored solutions for our clients.
Passionate about driving innovation and value in healthcare, our team leverages its extensive experience and multidisciplinary skills to navigate complex challenges and create impactful outcomes in global health economics and market access.
